AR121913A1 - Compuestos terapéuticos - Google Patents
Compuestos terapéuticosInfo
- Publication number
- AR121913A1 AR121913A1 ARP210101081A ARP210101081A AR121913A1 AR 121913 A1 AR121913 A1 AR 121913A1 AR P210101081 A ARP210101081 A AR P210101081A AR P210101081 A ARP210101081 A AR P210101081A AR 121913 A1 AR121913 A1 AR 121913A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heteroaryl
- alkoxy
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos que son activadores de Nrf2. Los compuestos tienen la fórmula estructural (1) que se define en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones que los comprenden y a su uso en el tratamiento de enfermedades o trastornos asociados con la activación de Nrf2. Reivindicación 1: Un compuesto según la fórmula (1) o la fórmula (2), o una sal farmacéuticamente aceptable de este, caracterizado porque: R¹ se selecciona entre alquileno-R¹¹ C₁₋₄, heterociclilo y heteroarilo bicíclico de 8 a 10 miembros, donde dicho heterociclilo está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, -C(O)-R¹², alquileno-OR¹⁴ C₁₋₃, SO₂-R¹³ y heteroarilo que está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, cicloalquilo C₃₋₇, halo, OH, alcoxi C₁₋₃ y ciano; y donde dicho heteroarilo bicíclico de 8 - 10 miembros está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, cicloalquilo C₃₋₇, halo, OH y alcoxi C₁₋₃; R² se selecciona entre hidrógeno, fluoro, cloro y alquilo C₁₋₃; R³ se selecciona entre hidrógeno, fluoro, cloro, bromo, alcoxi C₁₋₃, alquilo C₁₋₃, haloalquilo C₁₋₃ y ciano; R⁴ es hidrógeno o alquilo C₁₋₄; R⁵ es alquilo -C(O)-C₁₋₄, cicloalquilo -C(O)-C₃₋₇, heteroarilo-C(O)- o arilo-C(O)-, donde dicho heteroarilo y arilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de alquilo C₁₋₄, halo, hidroxi, alcoxi C₁₋₃, CO₂R¹⁵ y ciano; o R⁴ y R⁵, tomados junto con el átomo de nitrógeno al que se acoplan, de un anillo heterociclilo de 4, 5 ó 6 miembros, donde dicho anillo heterociclilo comprende una o más mitades -C(O)- acopladas al átomo de nitrógeno; opcionalmente contiene uno o más heteroátomos adicionales seleccionados del oxígeno, del nitrógeno y del azufre; opcionalmente está fusionado a un anillo arilo o heteroarilo; opcionalmente está acoplado en espiral a un grupo cicloalquilo C₃₋₇ o a un anillo heterociclilo de 3 a 6 miembros; y opcionalmente está sustituido por uno o más sustituyentes seleccionados de alquilo C₁₋₄, halo, OH, alcoxi C₁₋₃, haloalquilo C₁₋₃, ciano, NR¹⁶R¹⁷, C(O)R¹⁸, S(O)R¹⁹ y SO₂R²⁰; R⁶ se selecciona entre hidrógeno, alquilo C₁₋₄ y cicloalquilo C₃₋₇; R⁸ es C(=O)NR⁸ᵃR⁸ᵇ o -C(=O)R⁸ᶜ; R⁸ᵃ es hidrógeno o alquilo C₁₋₆; R⁸ᵇ es hidrógeno, alquilo C₁₋₆ o cicloalquilo C₃₋₇, donde los grupos alquilo C₁₋₆ o cicloalquilo C₃₋₇ están opcionalmente sustituidos con uno o más sustituyentes seleccionados de alquilo C₁₋₄, cicloalquilo C₃₋₇, halo, OH, alcoxi C₁₋₃, haloalquilo C₁₋₃, ciano, NR¹⁶R¹⁷, C(O)R¹⁸, S(O)R¹⁹ y SO₂R²⁰; o R⁸ᵃ y R⁸ᵇ, en conjunto con el átomo de nitrógeno al que están adheridos, forman un anillo heterocíclico de 3, 4, 5, 6 ó 7 miembros: opcionalmente contienen uno o más heteroátomos adicionales seleccionados del oxígeno, nitrógeno y azufre; y se sustituye opcionalmente con uno o más sustituyentes seleccionados de forma independiente de C₁₋₄alquil, C₃₋₇cicloalquil, halo, OH, C₁₋₃alcoxi, C₁₋₃haloalquil, ciano, NR¹⁶R¹⁷, C(O)R¹⁸, S(O)R¹⁹ y SO₂R²⁰; R⁸ᶜ es alquilo C₁₋₃, o haloalquilo C₁₋₃; R⁹ es metilo; R¹¹ se selecciona entre -C(O)-R²⁴, -SO₂-R²⁵, -NR²⁶C(O)-R²⁷, -NR²⁸SO₂-R²⁹, heterociclilo, arilo y heteroarilo, donde dichos grupos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de alquilo C₁₋₄, haloalquilo C₁₋₃, cicloalquilo C₃₋₇, alquileno-R³⁰ C₁₋₄, halo, OH, alcoxi C₁₋₃, heterociclilo y ciano; y dicho heterociclilo está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, haloalquilo C₁₋₃, cicloalquilo C₃₋₇, alquileno-R³⁰ C₁₋₄, halo, OH, alcoxi C₁₋₃, oxo y ciano; R¹² se selecciona entre alquilo C₁₋₄, cicloalquilo C₃₋₇, OR³¹, NR³²R³³, arilo y heteroarilo, donde dichos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, halo, OH, alcoxi C₁₋₃ y ciano; R¹³ se selecciona entre alquilo C₁₋₄, cicloalquilo C₃₋₇, heteroarilo, heterociclilo y NR³⁴R³⁵, donde dichos heteroarilo y heterociclilo están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, halo, OH, alcoxi C₁₋₃ y ciano; R¹⁷ se selecciona entre hidrógeno, alquilo C₁₋₄, alquilo C(O)C₁₋₃ y C(O)NR³⁶R³⁷; R¹⁸, R¹⁹ y R²⁰ se seleccionan independientemente de alquilo C₁₋₄, OH, alcoxi C₁₋₃ y NR³⁸R³⁹; R²⁴ se selecciona entre alquilo C₁₋₄, NR⁴⁰R⁴¹ y OR⁴²; R²⁵ se selecciona entre alquilo C₁₋₄ y NR⁴³R⁴⁴; R²⁷ se selecciona entre alquilo C₁₋₄, cicloalquilo C₃₋₇, haloalquilo C₁₋₃, heterociclilo, arilo y heteroarilo, donde dichos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, haloalquilo C₁₋₃, cicloalquilo C₃₋₇, alquileno-R⁴⁵ C₁₋₄, halo, OH, alcoxi C₁₋₃ y ciano; R²⁹ se selecciona entre alquilo C₁₋₄, cicloalquilo C₃₋₇, haloalquilo C₁₋₃, arilo y heteroarilo, donde dichos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, haloalquilo C₁₋₃, cicloalquilo C₃₋₇, alquileno-R⁴⁶ C₁₋₄, halo, OH, alcoxi C₁₋₃ y ciano; R³⁰ se selecciona entre hidroxi, alquilo C₁₋₃, cicloalquilo C₃₋₇, ciano y NR⁴⁷R⁴⁸; R⁴⁰ se selecciona entre manera de hidrógeno y alquilo C₁₋₄; R⁴¹ se selecciona entre hidrógeno, alquilo C₁₋₄, cicloalquilo C₃₋₇, alcoxi C₁₋₃, arilo y heteroarilo; o R⁴⁰ y R⁴¹, tomados junto con el átomo de nitrógeno al que se acoplan, de un anillo heteroarilo o heterociclilo de 4, 5 ó 6 miembros, donde dichos anillos heteroarilo o heterociclilo están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados de alquilo C₁₋₄, halo, OH, alcoxi C₁₋₃, C₃₋₇cicloalquilo y ciano; R⁴⁵ y R⁴⁶ se seleccionan independientemente de hidroxi, alcoxi C₁₋₃ y cicloalquilo C₃₋₇; y R¹⁴, R¹⁵, R¹⁶, R²⁶, R²⁸, R³¹, R³², R³³, R³⁴, R³⁵, R³⁶, R³⁷, R³⁸, R³⁹, R⁴², R⁴³, R⁴⁴, R⁴⁷ y R⁴⁸ se seleccionan independientemente de hidrógeno, alquilo C₁₋₄ y cicloalquilo C₃₋₇; siempre que el compuesto no sea (1S,2R)-2-((S)-5-cloro-8-((5-(difluorometil)-1-metil-1H-1,2,3-triazol-4-il)metoxi)-1-((2-oxopirrolidin-1-il)metil)-1,2,3,4-tetrahidroisoquinolina-2-carbonil)-1-metilciclohexano-1-carboxamida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2005852.5A GB202005852D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121913A1 true AR121913A1 (es) | 2022-07-20 |
Family
ID=70859963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101081A AR121913A1 (es) | 2020-04-22 | 2021-04-22 | Compuestos terapéuticos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230159511A1 (es) |
EP (1) | EP4139295A1 (es) |
JP (1) | JP2023524207A (es) |
KR (1) | KR20230004722A (es) |
CN (1) | CN115667242A (es) |
AR (1) | AR121913A1 (es) |
AU (1) | AU2021258539A1 (es) |
BR (1) | BR112022021370A2 (es) |
CA (1) | CA3174360A1 (es) |
GB (1) | GB202005852D0 (es) |
IL (1) | IL297440A (es) |
MX (1) | MX2022013396A (es) |
WO (1) | WO2021214472A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2963613T3 (es) * | 2018-10-22 | 2024-04-01 | C4X Discovery Ltd | Compuestos terapéuticos |
WO2023073364A1 (en) | 2021-10-25 | 2023-05-04 | C4X Discovery Limited | Tetrahydroisoquinoline compounds that are keap1 binders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
RU2018101077A (ru) * | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Регуляторы nrf2 |
JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
ES2963613T3 (es) | 2018-10-22 | 2024-04-01 | C4X Discovery Ltd | Compuestos terapéuticos |
-
2020
- 2020-04-22 GB GBGB2005852.5A patent/GB202005852D0/en not_active Ceased
-
2021
- 2021-04-22 BR BR112022021370A patent/BR112022021370A2/pt unknown
- 2021-04-22 EP EP21724005.0A patent/EP4139295A1/en active Pending
- 2021-04-22 IL IL297440A patent/IL297440A/en unknown
- 2021-04-22 KR KR1020227040564A patent/KR20230004722A/ko active Search and Examination
- 2021-04-22 WO PCT/GB2021/050975 patent/WO2021214472A1/en unknown
- 2021-04-22 AU AU2021258539A patent/AU2021258539A1/en active Pending
- 2021-04-22 US US17/920,244 patent/US20230159511A1/en active Pending
- 2021-04-22 CA CA3174360A patent/CA3174360A1/en active Pending
- 2021-04-22 AR ARP210101081A patent/AR121913A1/es unknown
- 2021-04-22 JP JP2022564532A patent/JP2023524207A/ja active Pending
- 2021-04-22 MX MX2022013396A patent/MX2022013396A/es unknown
- 2021-04-22 CN CN202180030434.4A patent/CN115667242A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230004722A (ko) | 2023-01-06 |
BR112022021370A2 (pt) | 2022-12-06 |
CN115667242A (zh) | 2023-01-31 |
JP2023524207A (ja) | 2023-06-09 |
US20230159511A1 (en) | 2023-05-25 |
EP4139295A1 (en) | 2023-03-01 |
WO2021214472A1 (en) | 2021-10-28 |
GB202005852D0 (en) | 2020-06-03 |
CA3174360A1 (en) | 2021-10-28 |
AU2021258539A1 (en) | 2022-11-10 |
IL297440A (en) | 2022-12-01 |
MX2022013396A (es) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
AR121913A1 (es) | Compuestos terapéuticos | |
AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
AR091368A1 (es) | Compuestos y composiciones para modular la actividad de egfr | |
AR103574A1 (es) | Compuestos tricíclicos y usos de lo mismos en medicina | |
AR109905A1 (es) | Pirrolidinas sustituidas como moduladores de cftr | |
AR114083A2 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
AR104259A1 (es) | Inhibidores de bromodominio | |
AR087747A1 (es) | Derivados de quinolona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
AR093413A2 (es) | Antagonistas de neuroquinina, composiciones farmaceuticas que los comprenden, y uso de dichos antagonistas en la preparacion de un medicamento | |
AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
AR113886A1 (es) | Derivados de indol macrocíclicos | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
AR099936A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR098436A1 (es) | Compuestos tricíclicos de piperidina | |
AR091464A1 (es) | Compuestos biciclicos de tiofenilamida | |
AR119156A1 (es) | Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma |